Our Take On Kala Pharmaceuticals [Seeking Alpha]
Kala Pharmaceuticals, Inc. (KALA)
Last kala pharmaceuticals, inc. earnings: 2/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.kalarx.com
Company Research
Source: Seeking Alpha
Summary Misery loved company, but damnation needed it. - John Connolly, The Wolf in Winter I got a question over the weekend from a Seeking Alpha follower on a small ocular concern whose stock has been cut in half since its IPO in 2017. We are updating some previous exclusive research that was provided to Busted IPO Forum members one month ago to present the investment analysis on this small cap concern in the paragraphs below. Company Overview: Kala Pharmaceuticals, Inc. ( KALA ) is a Waltham, Massachusetts based commercial stage biopharmaceutical delivery company initially focused on the development of therapeutics for the treatment of eye diseases. The company employs a proprietary nanoparticle-based Mucus Penetrating Particles ( MPP ) technology to deliver drugs more effectively to target tissues. In August 2018, Kala received its first FDA approval for INVELTYS (KPI-121 1.0%) for the treatment of inflammation and pain following ocular surgery. This ~$275 millio
Show less
Read more
Impact Snapshot
Event Time:
KALA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALA alerts
High impacting Kala Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALA
News
- KALA BIO, Inc. (NASDAQ: KALA) had its price target lowered by analysts at HC Wainwright from $22.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- KALA BIO, Inc. (NASDAQ: KALA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock.MarketBeat
- KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- KALA BIO to Present at TD Cowen 44th Annual Healthcare ConferenceGlobeNewswire
- KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewswire
KALA
Earnings
- 3/29/24 - Beat
KALA
Sec Filings
- 3/29/24 - Form 424B5
- 3/29/24 - Form S-8
- 3/29/24 - Form 10-K
- KALA's page on the SEC website